I think one of the opportunities for us in Canada is to have a regulatory system. A regulatory system is important. It builds confidence both domestically and internationally. What we have is a very complicated system that creates a lot of bottlenecks.
We celebrated the approval of gene editing by Health Canada, but we're still awaiting the CFIA's approval to be able to practice the technology. For perspective, that is about a decade behind where the United States was on the same ruling. Why do I know that? It was my team at Dow AgroSciences that led that first inquiry into the U.S. regulatory system. I think we need a process that's interactive and that can collaborate in work and provide feedback in real time to the companies that are submitting proposals, engaging stakeholders as well as the regulators.
Look, the COVID-19 vaccines went from idea to product in less than a year. We did not sacrifice safety and we did not sacrifice efficacy. It was done in a way that works. Again, we don't need a crisis to make the system work—